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Abstract
The associative striatum, an established substrate in psychosis, receives widespread glutamatergic projections. We
sought to see if glutamatergic indices are altered between early psychosis patients with and without a history of
cannabis use and characterise the relationship to grey matter. 92 participants were scanned: Early Psychosis with a
history of cannabis use (EPC= 29); Early Psychosis with minimal cannabis use (EPMC= 25); Controls with a history of
cannabis use (HCC= 16) and Controls with minimal use (HCMC= 22). Whole brain T1 weighted MR images and
localised proton MR spectra were acquired from head of caudate, anterior cingulate and hippocampus. We examined
relationships in regions with known high cannabinoid 1 receptor (CB1R) expression (grey matter, cortex, hippocampus,
amygdala) and low expression (white matter, ventricles, brainstem) to caudate Glutamine+Glutamate (Glx). Patients
were well matched in symptoms, function and medication. There was no significant group difference in Glx in any
region. In EPC grey matter volume explained 31.9% of the variance of caudate Glx (p= 0.003) and amygdala volume
explained 36.9% (p= 0.001) of caudate Glx. There was no significant relationship in EPMC. The EPC vs EPMC interaction
was significant (p= 0.042). There was no such relationship in control regions. These results are the first to demonstrate
association of grey matter volume and striatal glutamate in the EPC group. This may suggest a history of cannabis use
leads to a conformational change in distal CB1 rich grey matter regions to influence striatal glutamatergic levels or that
such connectivity predisposes to heavy cannabis use.
Introduction
A third of patients presenting with First Episode Psy-
chosis use cannabis regularly1. This dual diagnosis cohort
has a worse clinical outcome for days in hospital, relapses
and long term health2–5 not accounted for by potential
confounders such as alcohol, other drug use, adherence to
treatment and severity of illness at onset6, differences in
genetic make-up or premorbid environment7. Cessation
of cannabis use in patients with psychosis improves out-
come3, but is difficult to achieve8. Comorbid cannabis use
is associated with a higher incidence of treatment failure
in psychosis2. While there is some evidence that clozapine
reduces cannabis craving and use, there are no clear
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indications for superiority of any antipsychotic9. There are
no current effective pharmacological or psychological
interventions that can mitigate harm from cannabis use in
people with psychosis10,11. Hence, there is a pressing need
to understand the neurobiological alterations in the dual
diagnosis group, which may inform the development of
more effective treatments.
Positive psychotic symptoms may be underpinned by
increased presynaptic dopamine synthesis capacity12,13.
However there is limited evidence that cannabinoid
administration in humans increases dopaminergic sig-
nalling14. Positron Emission Tomography (PET) studies in
healthy volunteers with psychotic symptoms induced by
Δ-9-tetrahydrocannabinol (THC) administration showed
limited displacement of D2 receptor radioligand bind-
ing15–17. In cannabis users there is evidence of a blunting,
rather than increase of dopaminergic responses with no
relation between dopamine synthesis capacity and
induction of psychotic symptoms18. If cannabis use does
not increase striatal dopamine levels an alternative
mechanism must be sought to explain the psychosis-
cannabis association.
Psychosis also appears to be related to alterations in
brain glutamate function19,20. Glutamatergic perturba-
tions can be indexed using proton Magnetic Resonance
Spectroscopy (MRS), with abnormalities observed in
patients versus controls21. There are compelling rea-
sons to investigate the glutamate system within the
context of cannabis use in psychosis. Preclinical evi-
dence suggests an extensive disruption of the glutamate
function in the context of cannabinoid exposure22,
whereas chronic cannabis use appears to decrease glu-
tamate in otherwise healthy individuals22. The Cannabis
Receptor 1 (CB1R), the binding site for Δ-9-THC, pre-
dominantly found in axon terminals of the grey matter,
is amongst the most widely distributed G-Protein
Coupled Receptor in the brain with concentrations
10-50 times that of other neurotransmitters23. There
are widespread pyramidal projections from regions with
high CB1 receptor expression with the associative
striatum at the head of caudate where glutamate is the
primary neurotransmitter. At the synapse CB1R has
been proposed to be involved in post-synaptic hypo-
function of NMDA Receptor via receptor internalisa-
tion and CB1R has been noted to interact with
glutamate NMDA-Receptors to modulate long-distance
neural oscillatory activity24,25.
To date, only one study has examined glutamate levels
in patients with and without a history of cannabis use:
showing a decrease of Glx in the prefrontal cortex in
cannabis-using versus non-using patients with psy-
chosis26. However, this study neither examined changes in
other brain regions of interest nor did they include a
cannabis using, otherwise healthy control group.
In the context of dual diagnosis the striatal glutamate
has become a site of particular interest. Striatal glutama-
tergic levels, as typically indexed by glutamate+glutamine
(Glx) from Magnetic Resonance Spectroscopy, have been
shown to be elevated in patients during first presentation
of psychosis as compared to controls and a high risk
group versus controls27,28. Furthermore, two recent
double-bind randomised controlled studies have shown
an increase in striatal glutamate after administration of Δ-
9-THC in healthy volunteers29,30 and in one study this has
been shown to be associated with a perturbation of
cortico-striatal connectivity29.
Therefore, in the present study we investigated whether
glutamatergic indices were altered in early psychosis
patients with and without a history of cannabis use and in
a comparable group of otherwise healthy individuals with
and without a history of cannabis use. We hypothesized,
on the basis of pilot data that relative to patients without a
history of cannabis use, patients with a history of cannabis
use would show increased glutamatergic indices in brain
regions implicated in psychosis (anterior cingulate cor-
tex31,32, hippocampus33, and caudate34) and that levels in
patients would be greater than in controls. Given the
widespread distribution of the CB1R throughout the grey
matter35 and established pyramidal projections to the
associative striatum, we further hypothesized that regions
rich in CB1R expression (total grey matter, amygdala,
hippocampus, cortex) would be associated with caudate
Glx in patients with a history of cannabis use. As in
previous studies the primary metabolite of interest in all
regions was the composite Glx peak (glutamate+ gluta-
mine) as a marker of glutamatergic function, as it likely
reflects glutamate levels which are typically 5–6 times
higher than glutamine36, and has been shown to be
increased in the head of caudate in the two RCTs of acute
challenge of Δ-9-THC29,30 and in First Episode patients27.
Results for the Glutamate (Glu) metabolite are presented
as secondary analysis.
Methods
Sample
In the Effect of Cannabis in Psychosis (EfCiP) study
(London-Stanmore REC 17/LO/0577) we collected data
from four groups: patients with Early Psychosis with a
history of cannabis use (EPC), patients with early psy-
chosis with a minimal exposure to cannabis use (EPMC),
healthy control participants with a history of cannabis use
(HCC) and healthy control participants with minimal
exposure to cannabis use (HCMC). Informed consent was
obtained from all participants. Patients were referred from
Early Intervention in Psychosis services from 16 National
Health Service trusts in England. Controls were identified
from a register of healthy volunteers and individuals
expressing interest in cannabis research in an online
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survey37. Participants were aged 18–38 years and patients
were clinically stable on treatment. We excluded indivi-
duals with a diagnosis of organic psychosis. Infrequent
experimentation with cannabis is common in the general
population and therefore non-cannabis using participants
were defined as those having used cannabis ≤20 times in
their life. This cut-off for significant use is consistent with
previous studies38,39. All minimal cannabis users (EPMC,
HCMC) reported use a few times a year, only once or
twice or not at all; whereas all cannabis users (EPC, HCC)
reported use at least a few times each month, more than
weekly or daily (for full breakdown see Supplementary
Table 1). Final group allocation was made after Structured
Clinical Interview for DSM-IV (SCID) interview on the
study day.
Of 103 participants recruited, one HCC was excluded
due to cannabis intoxication, one HCMC was excluded
due to prolactinoma, two participants (EPMC) experi-
enced claustrophobia and were unable to have an MRI
scan, six participants (3 EPC, 3 EPMC) were not able to
have MRI due to contraindications to MRI scanning. One
patient had a first psychotic episode aged 12, 20 years and
was excluded. Data were available for 92 participants in
the study: EPC: n= 29, EPMC: n= 25; HCC: n= 16;
HCMC: n= 22.
Early psychosis was defined as presentation to second-
ary mental health services with psychosis within the last 5
years. This patient was currently under treatment of an
early intervention in psychosis team within the first 5
years and was retained in the study. One HCC suffered
from Generalised Anxiety Disorder on no treatment and
one HCC had Obsessive Compulsive Disorder 8 years
prior, currently in remission maintained on low dose
sertraline (50 mg).
Power
The study was powered prospectively based on effect-
size (Cohen’s d= 1.052) estimated from interim data from
a separate study in our laboratory comparing hippo-
campal glutamate in healthy cannabis users with non-
users (n= 19). A sample size of n= 16 per group was
required to detect differences between the EPC and
EPMC groups on 1H-MRS glutamate with an alpha (α) of
0.05 at 80% power. This was consistent with the only
previous study in patients in this area, subsequently
published, which found a significant difference in 17
cannabis users, 18 non-cannabis users and 35 controls26.
Clinical measures
Measures undertaken were the modified Cannabis
Experiences Questionnaire we have used before6, Time-
line Follow Back (TLFB) questionnaire40, Alcohol Use
Disorders Identification Test (AUDIT) score for alcohol
use in the preceding year41 and Fagerstrom Test for
Nicotine Dependence42. National Adult Reading Test
(NART) was applied for Intelligence Quotient estimation
based on a recently re-standardised calculation in British
adults43. Patients with diagnosis of mild Learning Dis-
ability (2 EPC, 2 EPMC) were assigned an estimated IQ of
65. All participants underwent Positive and Negative
Syndrome Scale (PANSS) and Structured Clinical Inter-
view for DSM-IV (SCID) interview (modules for mood,
psychosis and substance use as appropriate from the SCID
screening interview) to establish diagnosis and group
allocation by experienced raters alongside rating of Global
Assessment of Functioning (GAF). Participants under-
went Urine Drug Sample (UDS) for recent drug use
assessment.
Participants
were asked not to use cannabis or alcohol from the day
before scanning and not to drink coffee on the day prior
to the scan. Tobacco use was allowed to avoid withdrawal
effects. Participants were asked to abstain from cigarettes
from one hour before the scan however two participants
(EPC) had cigarettes 15 min before the scan. Exclusion of
their data in a sensitivity analysis showed no difference in
the main results.
Data acquisition
Data was acquired using a 32-channel Nova head coil
on a General Electric (Chicago, IL, USA) 3-Tesla
MR750 system. After a 3-plane localizer for orientation
and an ASSET calibration, volumetric T1 weighted MR
images were acquired using Sagittal ADNI Go Inversion
Recovery Spoiled Gradient Echo (IR-SPGR) sequence
with 196 1.2 mm thick slices were acquired with an in-
plane matrix size of 256 × 256 (1.05 mm× 1.05 mm) (TR/
TI/TE 7.312 ms/400ms/3.016 ms, flip angle: 11°).The field
of view was placed to avoid nose wrap. Total acquisition
time was 5 min 37 s.
MR Spectroscopy was undertaken using Point RESolved
Spectroscopy (PRESS) in three regions: a 2 × 2 × 2 cm3
voxel in the anterior cingulate and head of caudate and a
2 × 2 × 1.5 cm3 voxel in the hippocampus. Partial volume
correction was applied to all metabolites. For further
details of signal acquisition and partial volume correction
see Supplementary methods and sFig. 1.
Volume
T1 weighted MR images were processed using Free-
Surfer 6.0 Massachusetts General Hospital, Harvard
Medical School; http://surfer.nmr.mgh.harvard.edu). The
standard automated pipeline was applied using recon-all.
After motion correction the original volume was regis-
tered to MNI305 atlas44, intensity normalisation was
undertaken and skull stripping was performed. Sub-
cortical structures were segmented and labelled by
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registering images to the Freesurfer average atlas. The
following volumetric indices were extracted: total cerebral
grey matter (hereafter ‘grey matter’), total cerebral white
matter (hereafter ‘white matter’) and total ventricular
volume (sum of all ventricles, CSF and choroid plexus as
measured by FreeSurfer, hereafter ‘CSF’) as well as
volumes for left hippocampus, left amygdala, left cortex
and brainstem.
Quality control
Volumes
All structural images were visually inspected for motion
and MRI artifacts. After processing steps and further
visual inspection, manual edits were made to one scan, no
further edits were made and it was not necessary to
exclude any data.
MRS
Cramer-Rao lower bounds of ≥20% were excluded from
MRS analysis as these have been noted to have low
reliability. Cramer-Rao lower bounds of remaining scans
were checked to ensure there were no significant differ-
ences between groups (p > 0.45, all regions). For quality
parameters see Supplementary Table 2.
Statistics
Demographic and MRI volume data were compared
across groups using ANOVA tests for continuous mea-
sures and chi-squared tests or Fisher’s exact test (where
individual categories were ≤5) for categorical data.
Because the primary comparison of interest was EPC vs
EPMC all tests were also run for EPC vs EPMC using t-
tests and chi squared as appropriate.
As primary dependent variables: partial volume cor-
rected anterior cingulate, hippocampus and caudate Glx
levels were checked for normality using Shapiro-Wilks
test. ACC and caudate Glx were normally distributed; we
undertook logarithmic transformation for Hippocampal
Glx to correct positive skew.
To determine whether there was a group difference we
ran MANOVA model by entering patient status and
cannabis use as the independent variable, Glx levels for
the three regions as the dependent variables with follow-
up tests if significant. In a further sensitivity analysis we
adjusted the model (MANCOVA) covarying for age and
sex. To test specific hypotheses of differences between (i)
EPC vs EPMC and (ii) all patients and all controls we
undertook t-tests in each region. We set significance level
at p < 0.05.
To examine this further we undertook Pearson’s cor-
relations on total grey matter volume and caudate Glx by
group. We also ran correlations in control regions where
CB1 receptors are known to be low (white matter) or
absent (CSF). P value was Bonferroni-corrected to
account for multiple comparisons and groups (p < (0.05 ÷
12)= 0.0042).
To examine the relationship between caudate gluta-
matergic levels and specific grey matter regions known to
have high density of CB1 receptors and projections to the
caudate we undertook Pearson’s correlations on left cor-
tex, left hippocampus and left amygdala and caudate Glx
by group. We also included brain stem volume as a
control region where CB1 receptors are know to be low.
p-Value was Bonferroni-corrected to account for multiple
comparisons and groups (p < (0.05 ÷ 16)= 0.0031).
In sensitivity analyses we repeated these tests in grey
matter regions to ensure our results were robust to var-
iations in the following parameters: (i) using Glu instead
of Glx as the metabolite of interest; (ii) using alternative
methods of partial volume correction and (iii) using right
sided instead of left sided structures. As exploratory
sensitivity analyses we set p < 0.05. See Supplementary
Tables 3 and 4 for the full results.
To ensure that the relationship between grey matter and
caudate Glx in cannabis using patients was not accounted
for covariates we ran regression model in the EPC group
with caudate Glx as the dependent variables and grey
matter, age, sex, Fagerstrom (for smoking) and AUDIT
(for alcohol) scores as predictors in the model.
In further exploratory analysis we investigated if Glx
levels in any region (hippocampus, amygdala, caudate)
were correlated with clinical measures (PANSS, GAF, and
Chlorpromazine equivalents) in both patient groups.
Statistics were undertaken in SPSS version 25 (IBM,
Armonk, NY, USA).
Results
Patient demographics
Patients (EPC vs EPMC) were well matched across
clinical parameters including PANSS, GAF and anti-
psychotic dose in terms of chlorpromazine equivalents
(see Table 1). Cannabis users had higher AUDIT and
Fagerstrom scores than participants. As expected control
participants had higher estimated IQ scores than patients
but there was no difference between cannabis using and
non-using patients. There were no significant differences
in cannabis using parameters between EPC and HCC:
average age of first use of cannabis was 16.07 years (s.d.
2.51) for EPC and 16.00 years (s.d. 3.56) for HCC (p=
0.92); time to use an eighth of an ounce of cannabis (3.5
grams) was 9.56 days (s.d. 11.36) for EPC and 7.96 (s.d.
9.28) days for HCC (p= 0.68) and 12/29 (41%) EPC
participants tested positively on Urine Drug Sampling
versus 8/16 (50%) for HCC (p= 0.547).
Volume
There were no significant differences between EPC vs
EPMC for all volumes of regions and tissue classes of
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Table 1 Patient demographics.
EPC EPMC HCC HCMC p-Value
n 29 25 16 22
Sex 23/29 (79%) 16/25 (64%) 10/16 (63%) 11/22 (50%) All groups: 0.182
EPC vs EPNC: 0.210
Age 25.57 (3.89) 26.45 (5.04) 27.11 (5.95) 28.16 (5.29) All groups: 0.315
EPC vs EPNC: 0.476
Age at first presentation 23.56 (4.06) 24.10 (5.00) — — EPC vs EPNC: 0.565
AUDIT 8.79 (5.30) 3.40 (4.92) 7.75 (6.43) 3.59 (2.99) All groups: <0.001
EPC vs EPNC: 0.001
Fagerstrom 2.59 (2.44) 0.64 (1.52) 0.75 (1.73) 0 All groups: <0.001
EPC vs EPNC: 0.001
Proportion SSD 22/29 (76%) 19/25 (76%) none none EPC vs EPNC: 0.991
Diagnosis EPC vs EPNC: 0.459
Schizophrenia 11 (38%) 12 (44%)
Schizoaffective 8 (28%) 6 (24%)
Schizophreniform 3 (10%) 2 (8%)
Bipolar 2 (7%) 2 (8%)
Psychotic depression 1 (3%) 0
Brief psychotic D 1(3%) 2 (8%)
Psychosis NOS 0 2 (8%)
Substance induced 3 (10%) 0
Addiction comorbidity (lifetime)* All groups: <0.001EPC vs EPNC: 0.001
Cbs Dep 18 (62%) 0 6 (38%) 0
Cbs abuse 5 (17%) 0 2 (13%) 0
ETOH Dep 1 (3%) 1 (4%) 1 (6%) 0
ETOH abuse 4 (14%) 1 (4%) 2 (13%) 0
Other Dep 2(7%) 1 (4%) 1 (6%) 0
None 5 (17%) 22 (88%) 7 (44%) 22 (100%)
PANSS EPC vs EPNC: 0.526
Positive symptoms 12.17 (5.39) 11.24 (5.31) EPC vs EPNC: 0.806
Negative symptoms 13.93 (7.23) 14.40 (6.59) EPC vs EPNC: 0.905
General 27.14 (9.16) 26.84 (9.04) All groups: <0.001
Total 53.24 (18.49) 52.48 (17.46) 34.56 (5.38) 31.05 (2.13) EPC vs EPNC: 0.878
GAF 70.24 (8.98) 73.16 (11.21) 89.25 (4.93) 93.32 (2.64) All groups: <0.001
EPC vs EPNC: 0.293
CPZ equivalents 189.57 (174.15) 195.54 (172.43) none none EPC vs EPNC: 0.9
Antipsychotic Type EPC vs EPNC: 0.801
Atypical Oral 14 (48%) 11 (44%)
Typical 0 0
Clozapine 1 (3%) 1 (4%)
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interest (p > 0.16). There was a group effect of white
matter such that HCC had increased white matter com-
pared to HCMC and EPMC (see Table 2). When cor-
rected for intracranial volume there were no significant
differences between all groups for all regions and tissue
classes of interest both for all groups (p > 0.1) and for EPC
vs EPMC (p > 0.1).
Glutamate levels
There was no significant group effect for patients or can-
nabis users in anterior cingulate, hippocampus, and caudate
Glx and no significant patient x cannabis use interaction,
both in adjusted and unadjusted models (p > 0.26).
To test specific hypotheses we compared (i) EPC vs
EPMC and (ii) all patients versus all controls. There were
Table 1 continued
EPC EPMC HCC HCMC p-Value
Depot (all atypical) 4 (15%) 6 (24%)
None 10 (34%) 7 (28%)
Intelligence quotient 100.46 (12.73) 99.28 (14.59) 110.28 (6.93) 110.23 (7.97) All groups: 0.002
EPC vs EPNC: 0.768
Data presented in cells proportions for discrete data; means (standard deviations) for continuous data. p-Values are reported for omnibus tests (Chi squared, Fisher’s
exact where numbers in categories ≤5, ANOVA) for all groups: group-wise comparisons reported as appropriate (Chi squared, t-tests). EPC early psychosis with
cannabis use, EPMC early psychosis with minimal cannabis use, HCC healthy controls with cannabis use, HCMC healthy controls with minimal cannabis use, n number
of participants, SSD schizophrenia spectrum disorder, CPZ chlorpromazine. *Excludes nicotine (see Fagerstrom). Bold typeface indicates significance p < 0.05.
Table 2 Volume relationships between groups (mls).
EPC EPMC HCC HCMC p-Value
Grey matter 566.3 (61.3) 545.2 (47.5) 579.8 (61.3) 541.7 (40.8) All group: 0.085
EPC vs EPMC: 0.167
White matter 456.0 (57.1) 447.9 (48.1) 495.7 (59.8) 437.7 (51.6) All group: 0.011
HCC vs HCMC: 0.003
EPMC vs HCMC: 0.033
EPC vs EPMC: 0.575
CSF 18.18 (6.7) 19.2 (9.5) 21.5 (9.0) 16.9 (4.9) All group: 0.319
EPC vs EPMC: 0.653
L Caudate 3.51 (0.4) 3.4 (0.4) 3.7 (0.5) 3.4 (0.5) All group: 0.205
EPC vs EPMC: 0.182
L Hippocampus 4.14 (0.4) 4.0 (0.4) 4.3 (0.4) 4.1 (0.3) All group: 0.187
EPC vs EPMC: 0.305
L Amygdala 1.60 (0.2) 1.7 (0.2) 1.7 (0.3) 1.7 (0.3) All group: 0.274
EPC vs EPMC: 0.157
L Cortex 252.0 (27.8) 242.8 (21.8) 258.1 (27.5) 241.7 (18.5) All group: 0.110
EPC vs EPMC: 0.187
Brainstem 19.0 (2.3) 19.6 (2.0) 20.0 (2.7) 19.0 (1.8) All group: 0.421
EPC vs EPMC: 0.360
Intracranial volume 1363.3 (138.2) 1364.6 (176.3) 1459.9 (135.8) 1359.0 (136.4) All groups: 0.136
EPC vs EPMC: 0.975
All measures in cm3. Mean values given (standard deviations in brackets). EPC early psychosis with cannabis use, EPNC early psychosis with minimal cannabis use, HCC
healthy controls with cannabis Use, HCNC healthy controls with minimal cannabis use. Bold typeface indicates significance p < 0.05.
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no significant difference for either comparison in any
region. Caudate glutamate was elevated in EPMC com-
pared to EPC (p= 0.449). There was a trend level increase
for Caudate Glx in all patients compared to all controls (p
= 0.066) but this was not significant and remained at
trend level when accounting for different methods of
partial volume correction (CSF only: p= 0063, no cor-
rection: p= 0.54). Trend level significance did not remain
when Glu was used instead of Glx (p > 0.2). Glx levels by
group are shown in Fig. 1.
In exploratory analysis of metabolite levels there was no
significant group difference in any of the major metabo-
lites (Creatine; Glutamate; myo-inositol; N-acet-
ylaspartate; glycerophosphocholine+phosphocholine)
with acceptable Cramer-Rao Lower Bound thresholds in
any of the three voxels (p > 0.14). Full details are reported
in Supplementary Table 5.
Volume relationship with grey matter
Total grey matter volume was associated with caudate
Glx in cannabis-using patients but not in other groups
(EPC: r= 0.565, p= 0.003; see Fig. 2). This met the sig-
nificance threshold for EPC after multiple comparison
correction. No such correlation was seen in other groups
(see Fig. 2). The positive correlation seen in the grey
matter caudate Glx relationship in EPC was significantly
different from the correlation in the EPMC (one-tailed
Fisher r-to-z, z= 1.72, p= 0.042). In control tissue
regions there was no relationship in EPC for white matter
(r= 0.359, p= 0.072) or CSF with caudate Glx (r= 0.207,
p= 0.31).
In EPC a relationship between caudate Glx and volume
was shown in amygdala (r= 0.607, p= 0.001) with a trend
level in hippocampus (r= 0.520, p= 0.006) and left cortex
(r= 0.526, p= 0.006), but not brainstem (r= 0.339, p=
0.091) after multiple comparison correction. There were
no other significant findings for relationship between
caudate Glx and tissue class or region in any other groups.
Regression analyses showed grey matter and amygdala
volume to be a significant predictor of caudate Glx in
patients with a history of cannabis use (EPC) after co-
varying for AUDIT, Fagerstrom, age and sex (see Table 3).
Association of caudate Glx with clinical measures
There was no significant relationship of either patient
group for Glx in any region with PANSS, GAF or
Chlorpromazine equivalents.
Discussion
In three brain regions not previously studied we mea-
sured glutamatergic indices using an established bio-
marker (Glx) in psychosis21. This is the largest study to
date to examine glutamatergic indices in early psychosis
patients with and without a history of cannabis use. We
found no significant difference between the patient groups
and healthy control participants in total Glx across three
different regions implicated in psychosis.
A longitudinal study and meta-analytic evidence suggest
that increased Glx levels may be a state marker seen in
unmedicated patients with psychosis or early stages of
illness but not chronic illness or patients on treat-
ment21,27. Our patients were a clinically stable, treated
outpatient sample, with mean PANSS scores in the mild-
moderate range, exposure to antipsychotic treatment or
clinical stability may have normalised the glutamatergic
alteration21,45. Nonetheless a previous study found
reductions in glutamate levels in the prefrontal cortex
between cannabis and non-cannabis using patients with
early psychosis in a similarly treated sample26. In a larger
sample and across three different regions in a study
designed for this purpose, we do not replicate this finding.
Possible reasons for this include the use of different
regions of interest, differences in scanning parameters and
data acquisition, differences in partial volume correction
techniques and different cannabis use patterns amongst
samples.
This study is, however, the first to demonstrate an
association of grey matter volume and striatal glutamate
in patients with a history of cannabis use. We found a
strong positive relationship between total grey matter
volume and caudate Glx levels in cannabis using patients:
with grey matter volume explaining 31.9% of the variance
of caudate Glx and amygdala volume explaining 36.9% of
the variance of caudate Glx.
The CB1R is one of the most widely distributed G
Protein Coupled Receptors in the brain, with higher
expression in grey matter regions than white matter46.
Although CB1R density is high in the corpus striatum and
ventral striatum, in vitro evidence suggests these are not
the site of action for striatal dopamine release47. Of
interest our findings are demonstrated in the EPC group
(n= 26), and are at a trend level in the HCC group (n=
16). We had preferentially recruited patients in this study
but a sample size of 26 in HCC would be powered at 80%,
alpha 0.05 for the correlation coefficient we detect. It may
be that this association is a cannabis specific effect rather
than limited to EPC alone.
Given the cross-sectional nature of the study and the
uncertain nature of whether MRS indexes neuronal or
metabolic glutamate pools interpretation of these results
is by necessity speculative. Our results may suggest that
widespread distal projections to the caudate from dis-
tributed grey matter regions are implicated in caudate
glutamate signalling in patients with a history of cannabis
use. In such a model chronic cannabis use leads to a
conformational change in distal areas in the brain, parti-
cularly regions with high CB1R expression, which influ-
ence striatal glutamatergic levels through pyramidal
Sami et al. Translational Psychiatry          (2020) 10:111 Page 7 of 12
Fig. 1 Glx levels by regions across groups. EPC: early psychosis with cannabis use; EPMC: early psychosis without cannabis use; HCC: healthy
controls with cannabis use; HCMC: healthy controls without cannabis Use. Glx levels are partial volume corrected. Error bars are 95% confidence
Intervals.
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projections to the associative striatum. CB1Rs are found
in axonal terminals in the grey matter of glutamatergic
terminals and GABAergic interneurons48 and activation
can lead to both excitation or inhibition25,48. There is
evidence that chronic cannabis use downregulates CB1R
availability across the cortex and other grey matter
regions in at least a partially reversible manner49,50 and is
also involved in desensitization of CB1R activity22,51.
Perturbed endocannabinoid signalling in chronic cannabis
use may also be induced by widespread reductions in
Fatty Acid Amide Hydrolase indicating perturbation in
endocannabinoid signalling52,53, NMDA receptor inter-
nalisation35, or changes in long term depression and
potentiation54.
An alternative explanation, which is not mutually
exclusive, is that striatal glutamatergic levels affect total
grey matter volume. A previous MRS study that examined
glutamate metabolites in patients at clinical high risk for
psychosis, who were mostly cannabis users, found that
there were strong positive and negative correlations
between thalamic glutamate levels and grey matter
volume in several cortical regions55. These correlations
were much less evident in healthy controls. One inter-
pretation of these findings suggested by the authors was
that subcortical glutamate dysfunction in psychosis drives
loss of cortical grey matter volume. We, however, find this
less biologically plausible for the correlation between grey
matter volume and caudate Glx that we report as the
associative striatum where the voxel was placed is the
main afferent region for the basal ganglia receiving
widespread glutamatergic projections, but cannot com-
pletely discount this possibility. A further possibility is
that increased connectivity between cortical and sub-
cortical structures with glutamate in the associative
Table 3 Regression models for caudate glx in EPC.
Beta t Sig.
(a) Grey matter volume as a predictor of caudate Glx
Grey matter volume 0.617 2.658 0.015
Age 0.169 0.807 0.429
AUDIT score 0.152 0.733 0.472
Fagerstrom score 0.125 0.639 0.53
Sex −0.079 −0.329 0.746
(b) Amygdala volume as a predictor of caudate Glx
Left amygdala volume 0.647 2.794 0.011
AUDIT score 0.083 0.407 0.688
Age 0.054 0.28 0.782
Fagerstrom score 0.047 0.255 0.802
Sex 0.022 0.086 0.932
Bold typeface indicates significance p < 0.05.
R
R
2 =0.319, p=0.0
2 =0.203, p=0.0
03*  
8  
R2 =0.01
R2 =0.009
1, p=0.645 
, p=0.68 
Fig. 2 Grey matter volume by caudate Glx across groups. Grey matter measures in cm3. EPC: early psychosis with cannabis use; EPMC: early
psychosis without cannabis use; HCC: healthy controls with cannabis use; HCMC: healthy controls without cannabis use.
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striatum drives cannabis use. In the absence of long-
itudinal data we cannot disentangle these possibilities.
The strengths of this study are that it represents the
largest sample to have investigated this issue and that
clinical measures between EPC and EPMC were well
matched. Patients comprised a real-world sample recrui-
ted from 16 NHS Trusts throughout England. We inclu-
ded a cannabis using control arm which has been missing
from several previous studies in the field56. We used
optimised techniques to obtain volumes and absolute
metabolite concentrations in native space. Since both
signals were acquired in native space we did not correct
for intracranial volume as this would over-correct for the
relationship. ICV was matched across EPC and EPMC
groups and would not explain the difference between
groups. We checked to see if the same relationship existed
in different tissue classes using CSF and white matter as
control regions.
There are limitations of this study. The cross-sectional
nature of the current investigation means it is difficult to
disentangle causal relationships. It may be that the failure
to find group differences is due to a Type II error with
relatively modest sample sizes. Nonetheless we did power
this study from pilot data, and also a study published after
our pilot data also found differences between cannabis
and non cannabis using patients in a smaller sample (35
patients)26 whereas this study is the largest such study to
date. It is worth noting that powering a future study from
our findings (alpha 0.05, power 80%): 140 patients (70
EPC, 70 EPMC) would be required for powering a study
for the difference in Head of Caudate Glx; 680 (340 EPC,
340 EPMC) for powering a study for difference in hip-
pocampal Glx; and 832 patients (416 EPC, 416 EPMC) to
power a study in Anterior Cingulate Cortex. Hence the
group differences here, if they do exist, are small and
would require hundreds of patients (not including con-
trols) to detect.
There is the ever present issue of relying upon retro-
spective measures to ascertain cannabis use history56,57.
We did not collect data on the Duration of Untreated
Psychosis as should be undertaken in future studies. The
MRS signal does not distinguish between neuronal or
metabolic pools of glutamate. Furthermore the MRS Sig-
nal to Noise Ratio (SNR) differed between EPC and EPMC
groups in the caudate. We do not find this major limita-
tion as SNR was within acceptable limits in both groups
and there were no differences in other quality parameters.
Differences between SNR would not explain the correla-
tion between grey matter volume and caudate Glx seen in
the EPC group. We did not measure dopaminergic activity
which would be an important separate study to do.
Collectively we showed no alterations in glutamatergic
indices in patients with early psychosis with and without a
history of cannabis use. However, we find evidence for
altered volume/striatal glutamate relationships in patients
with a history of cannabis use. This adds to an accumu-
lating array of evidence26,29,30 which may suggest the
glutamate system as a target for therapy in the dual
diagnosis group.
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